Training patients’ own immune cells to recognize and destroy hard-to-treat solid tumors
Children’s National Hospital’s Center for Cancer and Immunology Research, led by Catherine “Cath” Bollard, M.B.Ch.B., is forging new frontiers in cancer immunotherapy, which reprograms a patient’s own immune cells so they learn to recognize and destroy cancer cells – and just cancer cells. This short video explains the lab’s use of a novel immune-directed, T-cell therapy to treat high-risk children and young adults with solid tumors who have few therapeutic options and face uncertain futures. STAT editors chose this research paper as one of the finalists in STAT Madness 2020, a bracket-style competition to highlight the year’s best biomedical innovations.
Vote NOW for Children’s National!
About the Expert
Catherine Bollard, M.D., M.B.Ch.B.
Director, Center for Cancer & Immunology Research
Bosworth Chair for Cancer Biology
Director, Program for Cell Enhancement and Technologies for Immunotherapy (CETI)
Attending Physician, Division of Bone and Marrow Transplantation
Jeffrey Dome, M.D., Ph.D.
Senior Vice President, Center for Cancer and Blood Disorders
Division Chief, Oncology
Conrad Russell Y. Cruz, M.D., Ph.D.
Principal Investigator, Program for Cell Enhancement and Technologies for Immunotherapies (CETI)
Director of the Translational Research Laboratories, Center for Emerging Technologies in Immune Cell Therapy
Patrick J. Hanley, Ph.D.
Chief and Director, Cellular Therapy Program
Associate Professor of Pediatrics